Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iSpecimen Inc.ISPC · Entity 8372 | Director | January 02, 2024 | May 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iSpecimen Inc.
Report date January 02, 2024 · Filed May 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2034-01-01 | Direct | 33,525 |
Reported balance
After 2024-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 10,000 · Balance 33,525 F1: Represents stock options granted to the reporting person on January 2, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan. The stock options vest respect to 2,500 shares on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted to the reporting person on January 2, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan. The stock options vest respect to 2,500 shares on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed May 20, 2024 15:18 UTC | iSpecimen Inc. ISPC · Entity 8372 | GrantOption · Derivative | 10,000 | $0.53 Strike: $0.53 | $5,300.00 |
DisclosureSEC source: 0001104659-24-063354 · tm2414962-1_4seq1.xml · derivative · entry 1 Brooks John L. III · CIK 0001343930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,525 Underlying: Common Stock · 10,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: Represents stock options granted to the reporting person on January 2, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan. The stock options vest respect to 2,500 shares on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. Read SEC document |
| January 03, 2023 Filed Jan 13, 2023 12:59 UTC | iSpecimen Inc. ISPC · Entity 8372 | GrantOption · Derivative | 10,000 | $1.41 Strike: $1.41 | $14,100.00 |
DisclosureSEC source: 0001104659-23-003745 · tm233286-3_4seq1.xml · derivative · entry 1 Brooks John L · CIK 0001343930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,525 Underlying: Common Stock · 10,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: Represents stock options granted to the reporting person on January 3, 2023, pursuant to the Issuer's Amended and Restated Stock Incentive Plan. The stock options vest respect to 2,500 shares on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| January 01, 2023 Filed May 17, 2023 12:37 UTC | iSpecimen Inc. ISPC · Entity 8372 | GrantCommon Stock | 125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-061741 · tm2315065-6_4seq1.xml · nonDerivative · entry 1 Brooks John L. III · CIK 0001343930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,250 F1 · security: Reflects shares of common stock issued to the Reporting Person upon vesting and settlement of restricted stock units ("RSUs") on March 31, 2023, which RSUs were awarded to the Reporting Person as of January 1, 2023, subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement. F1 · shares: Reflects shares of common stock issued to the Reporting Person upon vesting and settlement of restricted stock units ("RSUs") on March 31, 2023, which RSUs were awarded to the Reporting Person as of January 1, 2023, subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement. F2 · price: The RSUs were awarded as compensation to the Reporting Person for his service as a director of the Company. Read SEC document |
| October 01, 2022 Filed Feb 10, 2023 19:41 UTC | iSpecimen Inc. ISPC · Entity 8372 | GrantCommon Stock | 625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-018754 · tm236233-1_5seq1.xml · nonDerivative · entry 1 Brooks John L · CIK 0001343930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · security: Represents shares underlying certain restricted stock units ("RSUs"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the "RSU Agreement"). 625 RSUs vested in one installment on December 31, 2022 and were settled on January 3, 2023, subject to the terms and conditions set forth in the RSU Agreement and as a result, 625 shares of common stock were issued to the Reporting Person. F1 · shares: Represents shares underlying certain restricted stock units ("RSUs"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the "RSU Agreement"). 625 RSUs vested in one installment on December 31, 2022 and were settled on January 3, 2023, subject to the terms and conditions set forth in the RSU Agreement and as a result, 625 shares of common stock were issued to the Reporting Person. F2 · price: The RSUs were awarded as compensation to the Reporting Person for his service as a director of the Company. Read SEC document |
| July 30, 2021 Filed Feb 14, 2022 15:27 UTC | iSpecimen Inc. ISPC · Entity 8372 | GrantNon-Qualified Stock Options · Derivative | 13,525 | Not disclosed Strike: $8.00 | Not disclosed |
DisclosureSEC source: 0001104659-22-022553 · tm226491-2_5seq1.xml · derivative · entry 2 Brooks John L · CIK 0001343930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,525 Underlying: Common Stock · 13,525 shares Expires not disclosed F3 · security: Each non-qualified stock option ("NSO") represents a contingent right to receive one share of common stock upon exercise subject to the terms and conditions set forth in the award of such NSOs by iSpecimen Inc. (the "Company") to the Reporting Person pursuant to a Nonqualified Stock Option Award Agreement (the "NSO Agreement") under the iSpecimen Inc. 2021 Amended and Restated Stock Incentive Plan, as amended. The NSOs has a vesting term of three years with a one-year cliff (i.e. 33.33% of the NSOs vest on June 21, 2022, and the rest of the NSOs vest in equal quarterly installments on September 21, 2022 and each December 21, March 21, June 21 and September 21 until June 21, 2024), subject to the terms and conditions set forth in the NSO Agreement. F4 · price: The NSOs were awarded as compensation to the Reporting Person for his service as a director of the Company. F3 · derivative.exercise_date: Each non-qualified stock option ("NSO") represents a contingent right to receive one share of common stock upon exercise subject to the terms and conditions set forth in the award of such NSOs by iSpecimen Inc. (the "Company") to the Reporting Person pursuant to a Nonqualified Stock Option Award Agreement (the "NSO Agreement") under the iSpecimen Inc. 2021 Amended and Restated Stock Incentive Plan, as amended. The NSOs has a vesting term of three years with a one-year cliff (i.e. 33.33% of the NSOs vest on June 21, 2022, and the rest of the NSOs vest in equal quarterly installments on September 21, 2022 and each December 21, March 21, June 21 and September 21 until June 21, 2024), subject to the terms and conditions set forth in the NSO Agreement. F3 · derivative.expiration_date: Each non-qualified stock option ("NSO") represents a contingent right to receive one share of common stock upon exercise subject to the terms and conditions set forth in the award of such NSOs by iSpecimen Inc. (the "Company") to the Reporting Person pursuant to a Nonqualified Stock Option Award Agreement (the "NSO Agreement") under the iSpecimen Inc. 2021 Amended and Restated Stock Incentive Plan, as amended. The NSOs has a vesting term of three years with a one-year cliff (i.e. 33.33% of the NSOs vest on June 21, 2022, and the rest of the NSOs vest in equal quarterly installments on September 21, 2022 and each December 21, March 21, June 21 and September 21 until June 21, 2024), subject to the terms and conditions set forth in the NSO Agreement. Read SEC document |
| July 30, 2021 Filed Feb 14, 2022 15:27 UTC | iSpecimen Inc. ISPC · Entity 8372 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-022553 · tm226491-2_5seq1.xml · nonDerivative · entry 1 Brooks John L · CIK 0001343930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · security: Represents shares underlying certain restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Company to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the "RSU Agreement"). The RSUs vest in four equal installments on September 21, 2021, December 21, 2021, March 21, 2022 and June 21, 2022, subject to the terms and conditions set forth in the RSU Agreement. 625 RSUs and 625 RSUs were settled for shares of common stock on June 30, 2021 and December 31, 2021, respectively, and the Reporting Person was issued 1,250 shares of common stock. F1 · shares: Represents shares underlying certain restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Company to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the "RSU Agreement"). The RSUs vest in four equal installments on September 21, 2021, December 21, 2021, March 21, 2022 and June 21, 2022, subject to the terms and conditions set forth in the RSU Agreement. 625 RSUs and 625 RSUs were settled for shares of common stock on June 30, 2021 and December 31, 2021, respectively, and the Reporting Person was issued 1,250 shares of common stock. F2 · price: The RSUs were awarded as compensation to the Reporting Person for his service as the director of the Company. F1 · balance_after: Represents shares underlying certain restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Company to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the "RSU Agreement"). The RSUs vest in four equal installments on September 21, 2021, December 21, 2021, March 21, 2022 and June 21, 2022, subject to the terms and conditions set forth in the RSU Agreement. 625 RSUs and 625 RSUs were settled for shares of common stock on June 30, 2021 and December 31, 2021, respectively, and the Reporting Person was issued 1,250 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.